EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody



Successful treatment with a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with relapsed mantle cell lymphoma who developed a human anti-chimeric antibody



International Journal of Hematology 74(1): 70-75



Mantle cell lymphoma (MCL) has a poor prognosis without cure; the median overall survival ranges only from 3 to 4 years irrespective of conventional therapeutic regimens. IDEC-C2B8 (rituximab), a chimeric monoclonal antibody against the B-cell-specific antigen CD20, induces an evaluable clinical response in patients with MCL with mild toxicities. However, the single agent rituximab cannot cure MCL. Due to its low immunogenicity, an antibody against IDEC-C2B8 (human antichimeric antibody [HACA]) has rarely been produced in vivo. We report a patient with relapsed MCL who was successfully treated with IDEC-C2B8 for over a year although she developed HACA 6 months after the initial administration of IDEC-C2B8 in the phase II clinical trial conducted by Zenyaku Kogyo Co. Ltd. We followed the pharmacokinetics of IDEC-C2B8, the serum HACA titer, and the number of B lymphocytes in the peripheral blood in relation to clinical response. The HACA became undetectable soon after subsequent administrations of IDEC-C2B8. When the serum level of IDEC-C2B8 was kept elevated, clinical responses were apparently observed and HACA disappeared during this response period. There were no significant clinical toxicities related to the appearance of HACA. The present findings suggested that IDEC-C2B8 is effective and safe even in patients who have developed HACA.

(PDF emailed within 0-6 h: $19.90)

Accession: 011423884

Download citation: RISBibTeXText

PMID: 11530808

DOI: 10.1007/bf02982552



Related references

Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma. The IDEC-C2B8 Study Group. Annals of Oncology 9(5): 527-534, 1998

Analysis of bcl-2 t translocation in relapsed B-cell lymphoma patients treated with the chimeric anti-CD20 antibody IDEC-C2B8. Proceedings of the American Association for Cancer Research Annual Meeting 37(0): 213, 1996

Pharmacokinetics of the chimeric anti-CD20 antibody IDEC-C2B8 Analysis of serum concentrations in patients with relapsed B-cell lymphoma. British Journal of Haematology 93(SUPPL 2): 283, 1996

Pharmacokinetic analysis of serum concentrations of the chimeric anti-CD20 antibody IDEC-C2B8 in patients with relapsed B cell lymphoma. Proceedings of the American Association for Cancer Research Annual Meeting 36(0): 365, 1995

IDEC-C2B8 chimeric anti-CD20 antibody Safety and clinical activity in the treatment of patients with relapsed low-grade or follicular non-Hodgkins lymphoma. British Journal of Haematology 93(SUPPL 2): 283, 1996

IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 90(6): 2188-2195, 1997

Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biotherapy and Radiopharmaceuticals 12(3): 177-186, 1997

Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood 84(8): 2457-2466, 1994

Anti-CD20 chimeric antibody, IDEC-C2B8 Safety and clinical activity in the treatment of relapsed low grade or follicular lymphomas. Experimental Hematology (Charlottesville) 24(9): 1150, 1996

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Annals of Oncology 11 Suppl 1: 117-121, 2000

Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. Cellular Immunology 204(1): 55-63, 2000

Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. Biochemical Society Transactions 25(2): 705-708, 1997

Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab). Nihon Rinsho. Japanese Journal of Clinical Medicine 60(1): 95-99, 2002

Rituximab, a chimeric anti-CD20 monoclonal antibody, in the treatment of B-cell lymphoma. Gan to Kagaku Ryoho. Cancer & ChemoTherapy 29(3): 473-480, 2002

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology 16(8): 2825-2833, 1998